Opinion

Video

Factors for Consideration When Employing UASs In Patients With Urinary Stones

Author(s):

Michelle Semins, MD,Seth Bechis, MD

Drs Bechis and Semins discuss their approaches to employing ureteral access sheaths, reviewing assessing the ureter's caliber, dilation techniques, and the potential need for stenting post-sheath use, considering patient history and logistical factors like on-call availability.

Current Time 0:00
Duration 3:13
Loaded: 5.10%
Stream Type LIVE
Remaining Time 3:13
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Related Videos
    Christina Ching, MD, on study of follow-up after pediatric stone surgery
    Christina Ching, MD, on study of follow-up after pediatric stone surgery
    Marcelino Rivera, MD, on potential future advancements in stone disease, BPH
    Marcelino Rivera, MD, on potential future advancements in stone disease, BPH
    Human kidney stones | Image Credit: © freshidea - stock.adobe.com
    Future directions and research on the CVAC System for kidney stones
    Thomas Chi, MD, MBA, answers a question during a Zoom video interview
    Dr. Thomas Chi on the economics of the CVAC system for kidney stones
    Human kidney stones | Image Credit: © freshidea - stock.adobe.com
    How the CVAC System compares with URS for treating kidney stones
    Thomas Chi, MD, MBA, answers a question during a Zoom video interview
    Dr. Thomas Chi on the CVAC System for treating kidney stones
    Victoria S. Edmonds, MD, answers a question during a Zoom video interview
    Victoria S. Edmonds, MD, on reimbursement disparities for urolithiasis treatments
    Human kidney stones | Image Credit: © freshidea - stock.adobe.com
    Higher patient complexity associated with lower reimbursement for ureteroscopy
    Kari Tikkinen, MD, provides an update on the APPEAL trial
    Kari Tikkinen, MD, provides an update on the APPEAL trial
    DNA strand illustration | Image Credit: © Radomir Jovanovic - stock.adobe.com
    What criteria should be used when considering genetic testing in patients with stones?
    Related Content
    FDA updates in urology: February 2025
    March 3rd 2025

    FDA updates in urology: February 2025

    Hannah Clarke
    A recap of the FDA submissions and regulatory decisions in urology from February 2025.
    Why kidney stones will become more prevalent over time
    February 17th 2022

    Why kidney stones will become more prevalent over time

    Urology Times staff
    “The prevalence of kidney stones has increased over 80% over the last 30 years, and the epidemiology has changed such that it's beginning at a younger age now,” says Gregory Tasian, MD, MSc, MSCE.
    FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1
    February 5th 2025

    FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1

    Hannah Clarke
    A phase 1/2 trial of ABO-101 is expected to launch in the first half of 2025.
    Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters
    September 9th 2021

    Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters

    Urology Times staff
    “You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.
    Published ASPIRE data show noninferior stone-free rate with SURE vs URS
    December 23rd 2024

    Published ASPIRE data show noninferior stone-free rate with SURE vs URS

    Hannah Clarke
    The SURE procedure also demonstrated significantly better outcomes on the study’s secondary end points of stone clearance and residual stone volume.
    FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1
    December 19th 2024

    FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1

    Hannah Clarke
    The redePHine trial is expected to launch in the first half of 2025.
    © 2025 MJH Life Sciences

    All rights reserved.